Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY24 results · Jan–Mar 2024
Natco Pharma reported revenue from operations of ₹1,068.30 crore (up 19.0% from Q4 FY23) and net profit of ₹386.30 crore (up 40.1% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,068.30 | 897.90 | +19.0% | 758.60 | +40.8% |
| Other income | 42.00 | 29.00 | +44.8% | 37.00 | +13.5% |
| Total income | 1,110.30 | 926.90 | +19.8% | 795.60 | +39.6% |
| Profit before tax | 477.60 | 324.40 | +47.2% | 256.30 | +86.3% |
| Net profit for the period | 386.30 | 275.80 | +40.1% | 212.70 | +81.6% |
| EPS, basic (₹) | 21.56 | 15.11 | +42.7% | 11.88 | +81.5% |
| Net margin (%) | 36.2 | 30.7 | 28.0 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 964.80 | 781.20 | +23.5% | 625.30 | +54.3% |
| Other income | 35.90 | 17.50 | +105.1% | 29.50 | +21.7% |
| Total income | 1,000.70 | 798.70 | +25.3% | 654.80 | +52.8% |
| Profit before tax | 432.50 | 306.40 | +41.2% | 223.60 | +93.4% |
| Net profit for the period | 349.10 | 254.10 | +37.4% | 192.00 | +81.8% |
| EPS, basic (₹) | 19.49 | 13.92 | +40.0% | 10.72 | +81.8% |
| Net margin (%) | 36.2 | 32.5 | 30.7 |
Consolidated
- Filed with BSE
- 27 May 2024, 18:30 IST
- Board meeting
- 27 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 May 2024, 18:30 IST
- Board meeting
- 27 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE